Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

2002630 citationsJournal Articlebronze Open Access

Authors

Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB.

Good health and well-being

Published in: New England Journal of Medicine

Volume 347, Issue 7, pp. 481-487

Field-Weighted Citation Impact: 22.95